Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box protein 44 (FBXO44) is a substrate recognition subunit of the SCF (SKP1-CUL1-F-box protein) and CRL4B (CUL4B-DDB1-F-box protein) E3 ubiquitin ligase complexes, facilitating the ubiquitination and proteasomal degradation of specific substrates. Unlike other FBA family members, FBXO44 does not bind glycosylated proteins but instead recognizes substrates including BRCA1, a key regulator of DNA repair and cell cycle control, and RGS2, a regulator of G-protein signaling. FBXO44 plays critical roles in cellular protein turnover and is implicated in diseases such as breast and ovarian cancer (via BRCA1 regulation) and hypertension and anxiety (via RGS2 regulation). Although no approved drugs are known to target FBXO44 directly, its involvement in disease-associated pathways makes it an attractive therapeutic target.
Drugs targeting FBXO44 would act by inhibiting its E3 ligase catalytic activity, thereby preventing the ubiquitination and degradation of target proteins such as RGS2 and BRCA1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box protein 44 (FBXO44).